These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 23370482)

  • 1. Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview.
    Chaudhary AK; Pandya S; Ghosh K; Nadkarni A
    Mutat Res; 2013; 753(1):7-23. PubMed ID: 23370482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
    Das S; Amin SA; Jha T
    Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic Roles of Metalloproteinases in Hematological Malignancies: an Update.
    Chaudhary AK; Chaudhary S; Ghosh K; Nadkarni A
    Asian Pac J Cancer Prev; 2016; 17(7):3043-51. PubMed ID: 27509927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase inhibitors.
    Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
    Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
    Amin SA; Adhikari N; Jha T
    Pharmacol Res; 2017 Aug; 122():8-19. PubMed ID: 28501516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck.
    Chaudhary AK; Singh M; Bharti AC; Asotra K; Sundaram S; Mehrotra R
    J Biomed Sci; 2010 Feb; 17(1):10. PubMed ID: 20152059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
    Li W; Saji S; Sato F; Noda M; Toi M
    Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
    Zucker S; Cao J; Chen WT
    Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting.
    Abdel-Hamid NM; Abass SA
    Mol Biol Rep; 2021 Sep; 48(9):6525-6538. PubMed ID: 34379286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
    Winer A; Adams S; Mignatti P
    Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
    Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
    Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
    Yang JS; Lin CW; Su SC; Yang SF
    Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
    Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
    Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinases and the thyroid.
    Kraiem Z; Korem S
    Thyroid; 2000 Dec; 10(12):1061-9. PubMed ID: 11201850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the development of matrix metalloproteinase inhibitors.
    Tu G; Xu W; Huang H; Li S
    Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seesaw of matrix metalloproteinases (MMPs).
    Kapoor C; Vaidya S; Wadhwan V; ; Kaur G; Pathak A
    J Cancer Res Ther; 2016; 12(1):28-35. PubMed ID: 27072206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
    Mitsiades N; Poulaki V; Mitsiades CS; Anderson KC
    Expert Opin Investig Drugs; 2001 Jun; 10(6):1075-84. PubMed ID: 11772236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.
    Piperigkou Z; Manou D; Karamanou K; Theocharis AD
    Methods Mol Biol; 2018; 1731():325-348. PubMed ID: 29318564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases as therapeutic targets in cancer.
    Vihinen P; Ala-aho R; Kähäri VM
    Curr Cancer Drug Targets; 2005 May; 5(3):203-20. PubMed ID: 15892620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase inhibitors.
    Ramnath N; Creaven PJ
    Curr Oncol Rep; 2004 Mar; 6(2):96-102. PubMed ID: 14751086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.